Osimertinib-induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone

Tomoaki Takao; Kentaro Tanaka; Yoshimasa Shiraishi; Keiichi Ota; Yasuto Yoneshima; Eiji Iwama; Isamu Okamoto

doi:10.1016/j.cllc.2021.03.003

Osimertinib-induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone

Clin Lung Cancer. 2021 Sep;22(5):e784-e785. doi: 10.1016/j.cllc.2021.03.003. Epub 2021 Mar 16.

Authors

Tomoaki Takao¹, Kentaro Tanaka¹, Yoshimasa Shiraishi¹, Keiichi Ota¹, Yasuto Yoneshima¹, Eiji Iwama¹, Isamu Okamoto²

Affiliations

¹ Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
² Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Electronic address: okamotoi@kokyu.med.kyushu-u.ac.jp.

PMID: 33839042
DOI: 10.1016/j.cllc.2021.03.003

No abstract available

Keywords: Hyponatremia; Non-small cell lung cancer; Osimertinib; Syndrome of inappropriate secretion of antidiuretic hormone; Tyrosine kinase inhibitor.

Publication types

Case Reports

MeSH terms

Acrylamides / administration & dosage*
Acrylamides / adverse effects*
Aged
Aniline Compounds / administration & dosage*
Aniline Compounds / adverse effects*
Carcinoma, Non-Small-Cell Lung
Drug Substitution
Female
Humans
Inappropriate ADH Syndrome / chemically induced*
Treatment Outcome
Vasopressins / blood*

Substances

Acrylamides
Aniline Compounds
Vasopressins
osimertinib